Clinical trials: Tuberculosis, Latent
Tuberculosis, Latent Tuberculosis
Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)
The Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial) study will be a three-arm, open-label, parallel, randomized trial.
- Conditions
- Tuberculosis, Latent Tuberculosis, HIV/AIDS
- Trial name
- NCT03934931
- Testing
- Streamlined weekly DOT visits, Weekly DOT visit reminders, Cost reimbursement DOT
- Where
- Uganda
- Volunteers
- 1,656 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Latent Tuberculosis Infection, Tuberculosis
Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers
The aim of this study is to evaluate the safety of a new vaccine against Tuberculosis (RUTI) when administered to healthy adult volunteers, compared to placebo; and determine its safe dosage range.
- Trial name
- NCT00546273
- Testing
- RUTI
- Where
- 3 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Germans Trias i Pujol Hospital
Latent Tuberculosis
Tuberculosis Clinical Trials Consortium Study 35
Hypotheses: Rifapentine (given as water-dispersible monolayer and/or fixed dose combination with isoniazid) dosing in HIV-infected and uninfected children ≤ 12 years of age with latent TB infection (LTBI) or with exposure to…
- Trial name
- NCT03730181
- Testing
- Rifapentine, Isoniazid
- Where
- South Africa
- Volunteers
- 69 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis Infection, Isoniazid Adverse Reaction
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
This trial is designed to determine whether modifying the dose of isoniazid for individuals according to their n-acetyltransferase 2 (NAT2) genotype could increase the probability of achieving equivalence of area-under-the-curve.
- Trial name
- NCT05413551
- Testing
- Low-dose isoniazid, Standard dose of isoniazid, High-dose isoniazid
- Where
- Brazil
- Volunteers
- 78 people
- Sponsor
- Stanford University
Healthy, Latent Tuberculosis Infection (LTBI)
Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Background: Tuberculosis (TB) is a lung disease. It is caused by inhaling a type of airborne bacterium. Tuberculin Purified Protein Derivative (PPD) is used to test for TB exposure. It is usually injected under a person s skin.
- Trial name
- NCT05027958
- Testing
- Tuberculin Purified Protein Derivative
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)